Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical significance of antibody against oxidized low density lipoproteinin patients with atherosclerotic coronary artery disease
Autore:
Inoue, T; Uchida, T; Kamishirado, H; Takayanagi, K; Hayashi, T; Morooka, S;
Indirizzi:
Dokkyo Univ, Koshigaya Hosp, Dept Cardiol, Sch Med, Koshigaya, Saitama 3438555, Japan Dokkyo Univ Koshigaya Saitama Japan 3438555 igaya, Saitama 3438555, Japan
Titolo Testata:
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
fascicolo: 3, volume: 37, anno: 2001,
pagine: 775 - 779
SICI:
0735-1097(20010301)37:3<775:CSOAAO>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
OXIDATIVELY MODIFIED LDL; VITAMIN-E CONSUMPTION; MYOCARDIAL-INFARCTION; MONOCYTE-MACROPHAGES; VASCULAR-DISEASE; AUTOANTIBODIES; RISK; ATHEROGENESIS; MEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Inoue, T Dokkyo Univ, Koshigaya Hosp, Dept Cardiol, Sch Med, 2-1-50 Minamikoshigaya, Koshigaya, Saitama 3438555, Japan Dokkyo Univ 2-1-50 Minamikoshigaya Koshigaya Saitama Japan 3438555
Citazione:
T. Inoue et al., "Clinical significance of antibody against oxidized low density lipoproteinin patients with atherosclerotic coronary artery disease", J AM COL C, 37(3), 2001, pp. 775-779

Abstract

OBJECTIVES This study was designed to establish the clinical significance of antibodies against oxidized low density lipoprotein (anti-Ox-LDL) titer in atherosclerotic coronary artery disease (CAD). BACKGROUND Oxidative modification of LDL, which plays a kev role in the development of atherosclerosis, induces immunogenic epitopes in the LDL molecule, and the presence of anti-Ox-LDL has been demonstrated in human sera. METHODS Anti-Ox LDL titer was measured by enzyme-linked immunosorbent assay in 108 patients who had angiographically verified CAD, and 31 patients who had cHest pain but no significant CAD, as controls. RESULTS The anti-Ox-LDL titer was higher (p < 0.01) in patients with multivessel CAD (19.4 +/- 10.1 AcU/ml, n = 68) than in the controls (9.8 +/- 4.1). However, no significant difference was shown between the single-vessel CAD group (15.1 +/- 6.4, n = 40) and the controls, or between the multivessel CAD group and the single-vessel CAD group. The titer was higher in patients with unstable angina (21.5 +/- 11.8 AcU/ml, n = 20, p < 0.01), or in patients with acute myocardial infarction (23.1 +/- 12.0, n 20, p < 0.01) thanin patients with stable-effort angina or old myocardial infarction (12.2 +/- 8.6, n = 68). Multiple logistic regression analysis indicated that the anti-Ox-LDL titer most powerfully discriminated CAD patients from controls (odds ratio [OR]: 1.20, 95% confidence interval [CI]: 1.07-1.33, p = 0.0006)and acute coronary syndrome from chronic CAD (OR: 1.09, 95% CI: 1.04-1.14,p = 0.0008). CONCLUSIONS Serum anti-Ox-LDL titer not only can predict a presence of atherosclerotic CAD but also may be a marker of plaque instability. Low density lipoprotein oxidation may play an important role in the development of plaque instability. CT Am Cell Cardiol 2001;37:775-9) (C) 2001 by the American College of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 11:52:15